9-May-2024
Lenz Therapeutics’ Growth at Risk Amid IP Licensing Battles in Competitive Pharma Landscape
TipRanks (Fri, 10-May 2:00 AM ET)
Buy Rating Affirmed for LENZ Therapeutics Amidst Strong Clinical Progress and Market Potential
TipRanks (Fri, 10-May 1:27 AM ET)
TipRanks (Thu, 9-May 6:50 AM ET)
GAAP EPS of -$3.53 misses by $2.71
Seeking Alpha News (Wed, 8-May 5:10 PM ET)
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Globe Newswire (Wed, 8-May 4:01 PM ET)
LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024
Globe Newswire (Wed, 1-May 4:01 PM ET)
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
Business Wire (Wed, 3-Apr 7:00 AM ET)
Business Wire (Tue, 2-Apr 4:01 PM ET)
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
Lenz Therapeutics trades on the NASDAQ stock market under the symbol LENZ.
As of May 9, 2024, LENZ stock price declined to $15.40 with 115,261 million shares trading.
LENZ has a market cap of $393.22 million. This is considered a Small Cap stock.
Last quarter Lenz Therapeutics reported $0 in Revenue and -$3.53 earnings per share. This met revenue expectation and missed earnings estimates by -$2.69.
The top ETF exchange traded funds that LENZ belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
LENZ support price is $15.41 and resistance is $16.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LENZ stock will trade within this expected range on the day.